Research programme: Staphylococcus aureus infections - OSI PharmaceuticalsAlternative Names: Staphylococcal infections research programme - OSI Pharmaceuticals
Latest Information Update: 26 Jun 2002
At a glance
- Originator OSI Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 14 Apr 1999 Preclinical development for Staphylococcal infections in USA (Unknown route)